Skip to main content
TipRanks
Go Ultimate75% OFF

Draegerwerk AG & Co. KGaA (0MT8) AI Stock Analysis

0 Followers
GB:0MT8

Draegerwerk AG & Co. KGaA

(LSE:0MT8)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue and margin recoveryThe sharp recovery in revenue and profitability from the 2022 trough indicates improving operating execution and demand across the portfolio. Although margins remain moderate, continued progress in sales, gross profit, and operating earnings can rebuild earnings power and support investment over the next several quarters.
Negative Factors
Medical segment remains loss-makingMedical remains a drag on consolidated profitability despite year-over-year improvement, and its third-quarter earnings also declined. Continued losses could limit group margin expansion, consume management attention, and delay the point at which the company fully monetizes its healthcare installed base and product portfolio.

Draegerwerk AG & Co. KGaA (0MT8) vs. iShares MSCI United Kingdom ETF (EWC)

-10%0%10%20%30%40%50%60%GB:0MT8+49.19%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.59B
Dividend Yield
2.47%
Average Volume (3M)
323
Price to Earnings (P/E)
12.9
Beta (1Y)
0.56
Revenue Growth
5.06%
EPS Growth
40.18%
Country
UK
Employees
16,687
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Draegerwerk AG & Co. KGaA Business Overview & Revenue Model

Company Description

Headquartered in Lübeck, Germany, and established in 1889, Drägerwerk AG & Co. KGaA is an international enterprise specializing in medical and safety technology, with operations spanning Europe, the Americas, Africa, Asia, and Australia. For the heal...

Draegerwerk AG & Co. KGaA Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:15.80%|Next Earnings Date:Apr 30, 2025
Earnings Call SentimentPositive

The call was predominantly positive. Dräger reported strong nine-month order intake, sales, earnings, cash flow, balance-sheet improvement and Safety division momentum, confirmed full-year guidance, and highlighted the lifting of the FDA warning letter and opportunities in defense. These positives were tempered by third-quarter EBIT and Medical performance declines, higher functional expenses, a negative net tariff effect, weaker China demand, Americas and APAC pressure in specific areas, and the need for tight fourth-quarter cost management.

Positive Updates

Strong Nine-Month Top-Line and Earnings Growth
Order intake was around EUR 2.7 billion and noticeably above the high prior-year level. Net sales grew by around EUR 110 million to around EUR 2.5 billion, while earnings rose by roughly EUR 35 million to around EUR 112 million. The EBIT margin increased to 4.6%.

Negative Updates

Americas Order Intake Decline
Group order intake growth was supported by all regions except the Americas, which saw a significant decline as a result of a major hospital infrastructure systems order from Mexico in the second quarter of 2025.

Company Guidance

For the full year of 2026, Dräger confirmed guidance for net sales growth of 2% to 6%, net of currency effects, and an EBIT margin of 6% to 8%; the target remains unchanged to keep full year expense growth below net sales growth, free cash flow is expected to continue to develop positively, and the company expects order intake and sales to be better for the remainder of the year, with the fourth quarter being the best quarter. The goal to increase defense business from roughly EUR 100 million, which was had in around '25, to around EUR 300 million is unchanged, and the dividend policy remains unchanged at distributing at least 30% of net income as dividend.

Draegerwerk AG & Co. KGaA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0MT8 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:EUZDE:EUZ80OutperformEUR 922.97M16.6420.26%1.52%4.05%36.66%
DE:SHLDE:SHL77OutperformEUR 48.89B21.7011.72%2.33%1.09%3.52%
DE:AFXDE:AFX73OutperformEUR 2.89B19.105.52%1.72%-0.06%-38.81%
DE:M3VDE:M3V55NeutralEUR 38.95M28.957.77%4.32%-6.92%-67.82%
DE:SBSDE:SBS54NeutralEUR 347.66M-8.21-18.69%2.09%――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%GB:0MT8DE:AFXDE:EUZDE:M3VDE:SBSDE:SHLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0MT8 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0MT8Draegerwerk AG & Co. KGaA (0MT8)89.4029.4849.19%
DE:AFXCarl Zeiss Meditec31.90-12.11-27.52%
DE:EUZEckert & Ziegler Strahlen und Medizintechnik14.48-1.43-8.99%
DE:M3VMeVis Medical Solutions22.00-1.90-7.95%
DE:SBSSTRATEC Biomedical28.658.5042.16%
DE:SHLSiemens Healthineers42.961.774.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.